Etoposide
- PDF / 169,646 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 22 Downloads / 157 Views
1 S
Neutropenic fever: case report A 30-year-old woman developed neutropenic fever during treatment with etoposide for macrophage activation syndrome (MAS) secondary to Adult Onset Still’s Disease (AOSD). The woman was hospitalised for a two-week history of fevers, polyarthralgias and an erythematous rash. She was found to have anaemia, thrombocytopenia, splenomegaly, high ferritin and severe transaminitis. A bone marrow biopsy revealed hemophagocytosis. She was also found to have elevated soluble IL2 receptor and IL18 levels and low NK cell activity. Afterwards, she was discharged on prednisone and daily anakinra for MAS secondary to AOSD. However, after 2 weeks, she was again hospitalised for fevers and severe hemodynamic instability. She started receiving dexamethasone and etoposide [dosage and route not stated] for the treatment of relapsing MAS and AOSD. Her symptoms improved initially, but she developed neutropenic fever secondary to etoposide [duration of treatment to reaction onset not stated]. The woman’s etoposide was stopped and she was restarted on anakinra with a slow taper. Finally, she started receiving canakinumab. She responded well to canakinumab [outcome of adverse reaction not stated]. Bacalao M. Adult onset still’s disease treatedwith il1 inhibition. JCR: Journal of Clinical Rheumatology 20 (Suppl.): S143, No. 3, Apr 2020. Available from: URL: https:// 803520306 journals.lww.com/jclinrheum/Fulltext/2020/04001/22nd_PANLAR_Congress__Miami,_FL,_August_12_15_2020.1.aspx [abstract]
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
